{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:54:55Z","timestamp":1786114495324,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"DOI":"10.1007\/s00259-026-08117-5","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T09:03:07Z","timestamp":1785920587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genotype\u2013location interaction defines the SSTR-PET phenotype in paragangliomas and pheochromocytomas"],"prefix":"10.1007","author":[{"given":"Alessio","family":"Imperiale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Montanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Baltzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Canu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Fasciglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rapizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Hubele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Abenavoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Nerattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Zanatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Charpiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"8117_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","volume":"20","author":"D Ta\u00efeb","year":"2024","unstructured":"Ta\u00efeb D, N\u00f6lting S, Perrier ND, et al. Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement. Nat Rev Endocrinol. 2024;20:168\u201384.","journal-title":"Nat Rev Endocrinol"},{"key":"8117_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S2213-8587(25)00300-6","volume":"14","author":"K Pacak","year":"2026","unstructured":"Pacak K, Blake MA, Sweeney AT, et al. Adrenal tumour imaging: clinical, molecular, and radiomics perspectives. Lancet Diabetes Endocrinol. 2026;14:62\u201381.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"8117_CR3","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1210\/clinem\/dgad166","volume":"108","author":"A Fischer","year":"2023","unstructured":"Fischer A, Kloos S, Maccio U, et al. Metastatic pheochromocytoma and paraganglioma: somatostatin receptor 2 expression, genetics, and therapeutic responses. J Clin Endocrinol Metab. 2023;108:2676\u201385.","journal-title":"J Clin Endocrinol Metab"},{"key":"8117_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2967\/jnumed.118.211706","volume":"60","author":"S Han","year":"2019","unstructured":"Han S, Suh CH, Woo S, Kim YJ, Lee JJ. Performance of 68Ga-DOTA\u2013conjugated somatostatin receptor\u2013targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and meta-analysis. J Nucl Med. 2019;60:369\u201376.","journal-title":"J Nucl Med"},{"key":"8117_CR5","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","volume":"46","author":"D Ta\u00efeb","year":"2019","unstructured":"Ta\u00efeb D, Hicks RJ, Hindi\u00e9 E, et al. EANM practice guideline\/SNMMI procedure standard for radionuclide imaging of pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019;46:2112\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8117_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.humpath.2014.11.012","volume":"46","author":"MS Elston","year":"2015","unstructured":"Elston MS, Meyer-Rochow GY, Conaglen HM, et al. Increased SSTR2A and SSTR3 expression in succinate dehydrogenase\u2013deficient pheochromocytomas and paragangliomas. Hum Pathol. 2015;46:390\u20136.","journal-title":"Hum Pathol"},{"key":"8117_CR7","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","volume":"21","author":"I Janssen","year":"2015","unstructured":"Janssen I, Blanchet EM, Adams K, et al. Superiority of 68Ga-DOTATATE PET\/CT in SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res. 2015;21:3888\u201395.","journal-title":"Clin Cancer Res"},{"key":"8117_CR8","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s00259-015-3268-2","volume":"43","author":"A Archier","year":"2016","unstructured":"Archier A, Varoquaux A, Garrigue P, et al. Prospective comparison of 68Ga-DOTATATE and 18F-FDOPA PET\/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Eur J Nucl Med Mol Imaging. 2016;43:1248\u201357.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8117_CR9","doi-asserted-by":"publisher","first-page":"5150","DOI":"10.1210\/jc.2003-030262","volume":"88","author":"J Mundschenk","year":"2003","unstructured":"Mundschenk J, Unger N, Schulz S, et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab. 2003;88:5150\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"8117_CR10","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1097\/RLU.0000000000004870","volume":"48","author":"Y Zhi","year":"2023","unstructured":"Zhi Y, Gerhard-Hartmann E, Hartrampf PE, et al. Somatostatin receptor\u2013directed PET\/CT can differentiate between different subtypes of head and neck paragangliomas. Clin Nucl Med. 2023;48:923\u20137.","journal-title":"Clin Nucl Med"},{"key":"8117_CR11","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1007\/s00259-024-06735-5","volume":"51","author":"M Pepponi","year":"2024","unstructured":"Pepponi M, Berti V, Fasciglione E, et al. [68Ga]DOTATOC PET-derived radiomics to predict genetic background of head and neck paragangliomas: a pilot investigation. Eur J Nucl Med Mol Imaging. 2024;51:2684\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8117_CR12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.2967\/jnumed.115.161018","volume":"57","author":"I Janssen","year":"2016","unstructured":"Janssen I, Chen CC, Taieb D, et al. 68Ga-DOTATATE PET\/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT\/MRI. J Nucl Med. 2016;57:186\u201391.","journal-title":"J Nucl Med"},{"key":"8117_CR13","first-page":"1","volume":"1","author":"L Needleman","year":"2023","unstructured":"Needleman L, Enamandram S, Annes JP. Caution on the use of 68Ga-DOTATATE for the diagnosis of pheochromocytoma: a report of 2 cases. JCEM Case Rep. 2023;1:1\u20135.","journal-title":"JCEM Case Rep"},{"key":"8117_CR14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.2214\/AJR.21.26071","volume":"218","author":"A Jha","year":"2022","unstructured":"Jha A, Patel M, Carrasquillo JA, et al. Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET\/CT Using 68Ga-DOTATATE, FDG, 18F-FDOPA, and 18F-FDA. AJR Am J Roentgenol. 2022;218:342\u201350.","journal-title":"AJR Am J Roentgenol"},{"key":"8117_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40644-016-0084-2","volume":"16","author":"CA Chang","year":"2016","unstructured":"Chang CA, Pattison DA, Tothill RW, et al. 68Ga-DOTATATE and 18F-FDG PET\/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging. 2016;16:22.","journal-title":"Cancer Imaging"},{"key":"8117_CR16","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","volume":"78","author":"C Nioche","year":"2018","unstructured":"Nioche C, Orlhac F, Boughdad S, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumour heterogeneity. Cancer Res. 2018;78:4786\u20139.","journal-title":"Cancer Res"},{"key":"8117_CR17","first-page":"1342","volume":"46","author":"U Nestle","year":"2005","unstructured":"Nestle U, Kremp S, Schaefer-Schuler A, et al. Comparison of different methods for delineation of 18F-FDG PET\u2013Positive tissue for Target volume definition in Radiotherapy of patients with non\u2013small cell Lung Cancer. J Nucl Med. 2005;46:1342\u20138.","journal-title":"J Nucl Med"},{"key":"8117_CR18","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2967\/jnumed.117.199935","volume":"59","author":"F Orlhac","year":"2018","unstructured":"Orlhac F, Boughdad S, Philippe C, et al. Post-Reconstruction Harmonization Method for Multicenter Radiomic studies in PET. J Nucl Med. 2018;59:1321\u20138.","journal-title":"J Nucl Med"},{"key":"8117_CR19","doi-asserted-by":"crossref","unstructured":"Fischer A, Maccio U, Inukai JI, et al. [68Ga]Ga-DOTATATE uptake in pheochromocytoma\/paraganglioma predicts SSTR2 expression by immunohistochemistry: strongest uptake in head and neck paraganglioma. Eur J Nucl Med Mol Imaging. 2026 Jul;53(9):5462\u201374.","DOI":"10.1007\/s00259-026-07897-0"},{"key":"8117_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.mce.2007.09.009","volume":"286","author":"A Sch\u00f6nbrunn","year":"2008","unstructured":"Sch\u00f6nbrunn A. Selective agonism in somatostatin receptor signaling. Mol Cell Endocrinol. 2008;286:35\u201341.","journal-title":"Mol Cell Endocrinol"},{"issue":"Suppl 1","key":"8117_CR21","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1530\/eje.1.02354","volume":"156","author":"G Tulipano","year":"2007","unstructured":"Tulipano G, Schulz S. Novel insights in somatostatin receptor physiology. Eur J Endocrinol. 2007;156(Suppl 1):S3\u201311.","journal-title":"Eur J Endocrinol"},{"key":"8117_CR22","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00259-003-1184-3","volume":"30","author":"JC Reubi","year":"2003","unstructured":"Reubi JC, Waser B. Concomitant expression of several somatostatin receptor subtypes in human tumours: implications for in vivo targeting. Eur J Nucl Med. 2003;30:781\u201393.","journal-title":"Eur J Nucl Med"},{"key":"8117_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1210\/er.2000-0001","volume":"24","author":"LJ Hofland","year":"2003","unstructured":"Hofland LJ, Lamberts SWJ. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24:28\u201347.","journal-title":"Endocr Rev"},{"key":"8117_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrc3648","volume":"14","author":"PLM Dahia","year":"2014","unstructured":"Dahia PLM. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer. 2014;14:108\u201319.","journal-title":"Nat Rev Cancer"},{"key":"8117_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1530\/ERC-11-0243","volume":"19","author":"JS Fonte","year":"2012","unstructured":"Fonte JS, Robles JF, Chen CC, et al. False-negative \u00b9\u00b2\u00b3I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocr Relat Cancer. 2012;19:83\u201393.","journal-title":"Endocr Relat Cancer"},{"key":"8117_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1126\/science.288.5463.154","volume":"288","author":"M Rocheville","year":"2000","unstructured":"Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science. 2000;288:154\u20137.","journal-title":"Science"},{"key":"8117_CR27","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.ccr.2013.04.018","volume":"23","author":"E Letouz\u00e9","year":"2013","unstructured":"Letouz\u00e9 E, Martinelli C, Loriot C, et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell. 2013;23:739\u201352.","journal-title":"Cancer Cell"},{"key":"8117_CR28","doi-asserted-by":"publisher","first-page":"101416","DOI":"10.1016\/j.beem.2020.101416","volume":"34","author":"A Buffet","year":"2020","unstructured":"Buffet A, Burnichon N, Favier J, Gimenez-Roqueplo AP. An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab. 2020;34:101416.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"8117_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2967\/jnumed.125.270481","volume":"67","author":"G Belge Bilgin","year":"2026","unstructured":"Belge Bilgin G, Burkett BJ, Bilgin C, et al. Outcomes of Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Patients with Metastatic Pheochromocytoma and Paraganglioma. J Nucl Med. 2026;67:96\u2013104.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08117-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08117-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08117-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T21:02:13Z","timestamp":1785963733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08117-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":29,"alternative-id":["8117"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08117-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"1 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinky and was approved by local Institutional Review Board (2011\/0020149).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participants provided informed consent for publication.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DT is a cofounder, stakeholder, and the chief medical officer (CMO) of SILON Therapeutics and reports receiving advisory board honoraria from Novartis. The other authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}